Results 61 to 70 of about 2,415,366 (239)

The sRNA vvrr1 Modulates the VarS/VarA‐Csr System via LeuO to Regulate Biofilm Formation and Virulence in Vibrio alginolyticus

Animal Research and One Health, EarlyView.
vvrr1, a small RNA, post‐transcriptionally represses the transcriptional regulator LeuO, which directly inhibits the VarS/VarA two‐component system. This triggers a Csr cascade that relieves LuxO repression, ultimately modulating exopolysaccharide production to control biofilm formation and virulence in Vibrio alginolyticus.
Theerakamol Pengsakul, Lei Wen, Lingmin Zhao, Bei Huang, Jiang Zheng, Binfu Xu, Lixing Huang   +6 more
wiley   +1 more source

Inhibition of rifampicin‐resistant RNA synthesis by rifampicin—RNA polymerase complexes

FEBS Letters, 1974
Biochemical and electron microscopic evidence has shown that Escherichia coli RNA polymerase holoenzyme forms in vitro, in the absence of nucleoside triphosphates, a stable and specific complex with bacteriophage T7 DNA in the early promoter region of the chromosome [ 1,2].
openaire   +2 more sources

Detection of Rifampicin Resistance in HIV Seropositive Individuals with Suspected Pulmonary Tuberculosis by Using CBNAAT

, 2017
Tuberculosis(TB) remains the most common opportunistic infection among people living with HIV (PLHIV) and diagnosing it becomes a challenging task as sputum microscopy is negative in more than half of the patients.
Shilpa, Shilpa Shilpa, Shobha D. Nadagir, Jnaneshwara KB, Jnaneshwara K.B., Shobha Nadagir, Asha Patil, Aaftab G. Pendari, Uma Chikkaraddi, Aaftab Pendari, Asha B. Patil   +10 more
core   +1 more source

Population pharmacokinetics of levofloxacin in breastmilk in patients with rifampicin‐resistant tuberculosis

British Journal of Clinical Pharmacology, EarlyView.
Levofloxacin is a widely used antibiotic included in rifampicin‐resistant tuberculosis (RR‐TB) treatment. Data describing levofloxacin concentrations in breastmilk and infant exposure are limited. We analysed data from two South African studies of breastfeeding women receiving levofloxacin (750–1000 mg daily) for RR‐TB.
Sharon Sawe, Lufina Tsirizani, Buyisile Mkhize, Lubbe Wiesner, Gary Maartens, Francesca Conradie, Richard Court, Marian Loveday, Catriona Waitt, Paolo Denti   +9 more
wiley   +1 more source

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension

British Journal of Clinical Pharmacology, EarlyView.
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien, Burabha Pussadhamma, Sirimas Kanjanawart, Thikhumporn Areesinpitak, Nontaya Nakkam, Chingching Foocharoen, Wichittra Tassaneeyakul, Suda Vannaprasaht   +7 more
wiley   +1 more source

High isoniazid resistance rates in rifampicin susceptible Mycobacterium tuberculosis pulmonary isolates from Pakistan.

PLoS ONE, 2012
BackgroundRapid new diagnostic methods (including Xpert MTB/RIF assay) use rifampicin resistance as a surrogate marker for multidrug resistant tuberculosis. Patients infected with rifampicin susceptible strains are prescribed first line anti-tuberculosis
Naima Fasih, Yasraba Rafiq, Kausar Jabeen, Rumina Hasan   +3 more
doaj   +1 more source

Rapid onset and offset of the interaction between rifampicin and long‐acting cabotegravir/rilpivirine: A pharmacokinetic case report

British Journal of Clinical Pharmacology, EarlyView.
Long‐acting intramuscular cabotegravir/rilpivirine (LA CAB/RPV) is contraindicated with rifampicin because of the risk of markedly reduced antiretroviral exposure, although clinical pharmacokinetic data for this interaction are lacking. We describe a 49‐year‐old man with virologically suppressed HIV‐1 infection receiving LA CAB/RPV every 8 weeks who ...
Emilie M. Gieling, Lisanne A. H. Bevers, Wouter L. Smit, Rosa H. Elias, Annelies Verbon, David M. Burger, Berend J. van Welzen   +6 more
wiley   +1 more source

Advanced In Vitro Platforms for Experimental Liver Research: From Organoids and Liver‐on‐Chip to Omics and Artificial Intelligence

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Hepatocytes perform essential physiological functions in the human body. Gaining more profound insight into the liver structure, diseases, and physiology by using in vitro models can help to propose more relevant clinical applications. Conventional in vitro liver models, such as two‐dimensional (2D) cell cultures, fail to adequately replicate ...
Seyedeh Kiana Teymorian, Pedram Asadi Sarabi, Abbas Piryaei, Massoud Vosough   +3 more
wiley   +1 more source

Plasmid-mediated rifampicin resistance in Pseudomonas fluorescens [PDF]

Journal of Medical Microbiology, 1998
Rifampicin is an antibiotic mostly used to treat tuberculosis and leprosy, and, occasionally, other diseases. Resistance is due to alterations in membrane permeability or to mutation in the rpoB gene coding for mRNA polymerase. Both these mechanisms originate via chromosomal mutation.
S, Chandrasekaran, D, Lalithakumari
openaire   +2 more sources

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source